| Literature DB >> 18471299 |
Manuel W Hetzel1, Angel Dillip, Christian Lengeler, Brigit Obrist, June J Msechu, Ahmed M Makemba, Christopher Mshana, Alexander Schulze, Hassan Mshinda.
Abstract
BACKGROUND: Throughout Africa, the private retail sector has been recognised as an important source of antimalarial treatment, complementing formal health services. However, the quality of advice and treatment at private outlets is a widespread concern, especially with the introduction of artemisinin-based combination therapies (ACTs). As a result, ACTs are often deployed exclusively through public health facilities, potentially leading to poorer access among parts of the population. This research aimed at assessing the performance of the retail sector in rural Tanzania. Such information is urgently required to improve and broaden delivery channels for life-saving drugs.Entities:
Mesh:
Substances:
Year: 2008 PMID: 18471299 PMCID: PMC2405791 DOI: 10.1186/1471-2458-8-157
Source DB: PubMed Journal: BMC Public Health ISSN: 1471-2458 Impact factor: 3.295
Figure 1Examples of a part II drug store (left) and a general shop (right). Both shop types are providers of malaria treatment in rural Tanzania.
Malaria symptoms mentioned most frequently by shopkeepers (N = 489)
| N | 29 | 460 | |
| Fever | 86 (68–96) | 60 (56–65) | |
| Headache | 86 (68–96) | 40 (36–45) | |
| Joint pains | 62 (42–79) | 39 (34–44) | |
| Vomiting | 86 (68–96) | 33 (28–37) | |
| Malaise | 31 (15–51) | 20 (16–24) | 0.138 |
| Feeling cold | 17 (6–36) | 16 13–20) | 0.895 |
| Poor appetite | 21 (8–40) | 10 (7–13) | 0.063 |
| Weakness | 28 (13–47) | 7 (5–10) | |
| Diarrhoea | 28 (13–47) | 6 (4–8) | |
| Dizziness | 14 (4–32) | 4 (2–6) | |
| Don't know | 0 (0–12) | 12 (9–15) | 0.053 |
| Changed behaviour | 24 (10–44) | 17 (14–21) | 0.326 |
| Unconsciousness/coma | 17 (6–36) | 7 (5–10) | 0.059 |
| Weakness | 35 (18–54) | 18 (15–22) | |
| Anaemia | 10 (2–27) | 1 (0–2) | |
| Convulsions ( | 52 (33–71) | 10 (7–13) | |
| Splenomegaly ( | 3 (0–18) | 0 (0–1) | |
| High fever | 79 (60–92) | 44 (39–38) | |
| Don't know | 3 (0–18) | 27 (23–32) | |
* Wilcoxon rank sign test
Shopkeepers' understanding of the recommended treatment of uncomplicated malaria (N = 489)
| N | 29 | 460 | |
| Referral to health facility | 3 (0–18) | 34 (30–39) | |
| Antipyretic | 55 (36–74) | 31 (27–35) | |
| Antimalarial | 90 (73–98) | 32 (28–36) | |
| - SP | 66 (46–82) | 12 (9–16) | |
| - SP + PCM | 35 (18–54) | 5 (3–7) | |
| - SP correct dose | 52 (33–71) | 3 (2–5) | |
| - SP correct dose + PCM | 31 (15–51) | 1 (0–2) | |
| Referral to HF† | 0 (0–12) | 24 (20–28) | |
| Antipyretic | 55 (36–74) | 44 (39–49) | 0.237 |
| Antimalarial | 93 (77–99) | 54 (49–58) | |
| - SP | 79 (60–92) | 35 (31–40) | |
| - SP + PCM | 48 (29–68) | 16 (13–19) | |
| - SP correct dose | 76 (57–90) | 29 (25–33) | |
| - SP correct dose + PCM | 45 (26–64) | 14 (11–18) | |
SP = Sulphadoxine-pyrimethamine; PCM = Paracetamol.
* Wilcoxon rank sign test.
‡ Double-mentioning possible.
† one-sided, 97.5% confidence interval.
Figure 2Flow-chart of mystery shoppers study. Case scenarios: A = child, aged 2–4 months; B = child, aged 2–4 years; C = adult. Refer to main text for details.
Number of shops that dispensed drugs to mystery shoppers
| Ulanga DSS | 2/2 (100) | 23/30 (77) | 25/32 (78) |
| Kilombero DSS | 10/10 (100) | 20/44 (46) | 30/54 (56) |
| Ifakara | 5/8 (63) | 10/24 (42) | 15/32 (47) |
Types of medicines sold to mystery shoppers
| N | 17 | 53 | ||
| SP | 6 | 35 | 5 | 9 |
| Amodiaquine | 6 | 35 | 4 | 8 |
| Quinine | 4 | 24 | 0 | |
| Any antimalarial | 15 | 88 | 10 | 19 |
| Paracetamol | 14 | 82 | 39 | 74 |
| Any antipyretic | 15 | 88 | 45 | 85 |
| Antibiotic | 2 | 12 | 2 | 4 |
| Vitamin B complex | 5 | 29 | 0 | |
| SP & paracetamol | 6 | 35 | 3 | 6 |
| Amodiaquine & paracetamol | 4 | 24 | 2 | 4 |
| Quinine & paracetamol | 4 | 24 | 0 | |
| SP & quinine | 1 | 6 | 0 | |
| Antimalarial & antibiotic | 2 | 12 | 0 | |
Univariate and multivariate logistic regression analysis of the relationship between (any) antimalarial drug obtained and selected predictors (all visited shops)
| - Child 2–4 months | 43 | 1 | 1 | ||
| - Child 1–4 years | 33 | 0.85 (0.22–3.30) | 0.815 | 0.62 (0.09–4.00) | 0.612 |
| - Adult | 42 | 3.43 (1.18–9.98) | 0.024 | 9.30 (1.70–50.92) | |
| - General shop | 98 | 1 | 1 | ||
| - Drug store | 20 | 26.40 (7.91–88.10) | <0.001 | 76.47 (13.07–447.50) | |
| - Ifakara | 32 | 1 | 1 | ||
| - DSS | 86 | 0.95 (0.35–2.53) | 0.911 | 1.65 (0.41–6.66) | 0.480 |
* Wald test of significance of effect
Linear regression model of predictors of higher expenditures for antimalarial drugs
| - Child 2–4 months | 20 | 1 | 1 | ||
| - Child 1–4 years | 22 | -0.12 (-0.42 to 0.18) | 0.423 | -0.16 (-0.37 to 0.05) | 0.124 |
| - Adult | 26 | -0.15 (-0.44 to 0.13) | 0.285 | -0.25 (-0.45 to -0.06) | |
| 68 | 0.19 (0.11 to 0.27) | <0.001 | 0.12 (0.05 to 0.19) | ||
| - General shop | 50 | 1 | 1 | ||
| - Drug store | 18 | 0.75 (0.56 to 0.95) | <0.001 | 0.59 (0.38 to 0.80) | |
| - Ifakara | 15 | 1 | 1 | ||
| - DSS | 53 | -0.11 (-0.39 to 0.17) | 0.434 | -0.06 (-0.24 to 0.13) | 0.548 |
*Wald test of significance of effect